Current clinical criterion can only identify 5% of high risk stroke patients. Tenoke, considering plaque component and its mechanical loading can identify 100%. The software is fast, standardized and semi-automated MR image-based analysis tool which can be installed on most of computers. We first offer risk assessment report to consumers and when we have FDA approval we can license SPACE to hospitals. We need £1 million to set up the business and anticipate £57.5m revenue in the first 5 years.
Tenoke has developed a software (SPACE) to accurately assess plaque vulnerability to predict the risk of stroke.